Hosted on MSN3mon
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series ... Deep Track Capital and Frazier Life Sciences co-led the financing round, with Logos Capital and Janus Henderson Investors also taking part.
Business Insider1mon
Maze Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, could address the majority of the over 1M APOL1 ...